Article Sidebar
Views pdf: 249
EVALUATION OF RESULTS OF AFATINIB TREATMENT OF STAGE IIIB-IV NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION
Main Article Content
Abstract
Objective: To evaluate the results Afatinib treatment in the stage IIIB-IV non-small cell lung cancer with Afatinib at National Lung Hospital. Patients and methods: 45 advanced and metastatic non-small cell lung cancer patients with EGFR mutations were treated with afatinib at National Lung Hospital from September 2020 to September 2023. Results: 68.9% of patients achieved a complete response, 24.4% of patients stabilized; disease control rate reached 93.3%.The response rate for each type of lesion was as follows: contralateral lung metastases (65%); central nervous system metastasis (77,8%); adrenal metastases (66.7%). The response rate in the group of patients with common EGFR mutations was 64.7% and in the rare group was 81.8%. The progresson-free survival (PFS) was 13,5 months, with no significant difference between patients with common EGFR mutations (13,6 months) and those with uncommon EGFR mutations (13,4 months). The most common adverse effects were diarrhea (82.2%) and skin rash (46.7%) mainly in grade 1 and grade 2. No patient died from unwanted side effects. Conclusions: Patients with stage IIIB-IV non-small cell lung cancer with EGFR gene mutations treated with Afatinib have a high response rate and good tolerability, including those with both common and uncommon EGFR mutations.
Article Details
Keywords
Non-Small Cell Lung Cancer, EGFR, Afatinib
References
2. Nguyễn Hoài Nga TVT, Bùi Diệu và CS. Một số đặc điểm dịch tễ, lâm sàng, cận lâm sàng ung thư phổi nguyên phát chẩn đoán điều trị tại bệnh viện K trong 10 năm từ 2001 đến 2010. 2011;2(7)
3. Shi Y, Au JS-K, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology (PIONEER). Journal of thoracic oncology. 2014;9(2):154-162.
4. Yang JC-H, Schuler MH, Yamamoto N, et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. American Society of Clinical Oncology; 2012.
5. Wu Y-L, Zhou C, Hu C-P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. The lancet oncology. 2014;15(2):213-222.
6. Paz-Ares L, Tan E-H, O’Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Annals of Oncology. 2017;28(2):270-277.
7. Liang S-K, Lee M-R, Liao W-Y, Ho C-C, Ko J-C, Shih J-Y. Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study. Oncotarget. 2018;9(34):23749.
8. Brueckl W, Laack E, Reck M, et al. Efficacy of afatinib in the clinical practice: First results of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany. Annals of Oncology. 2018;29:viii524.
9. Võ Thị Huyền Trang, Phạm Cẩm Phương. Đánh giá kết quả Afatinib điều trị ung thư phổi không tế bào nhỏ giai đoạn IIIB-IV có đột biền EGFR. Tạp chí Y học Việt Nam. 2021;1(Tháng 11):508.
10. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. The lancet oncology. 2015;16(7):830-838.